Explore

Recent news and media from the Citizen Stash squad.

Experion Holdings Ltd. Signs LOI with the Société Québécoise du Cannabis (SQDC) to Supply Cannabis Products for Distribution and Sale in the Province

VANCOUVER, BC and MONTREAL, QC, September 10, 2019 (FSCwire) Experion Holdings Ltd. (TSXV: EXP) (OTCQB:EXPFF) (FRANKFURT:MB31), formerly Viridium Pacific Group Ltd today announced that its wholly-owned subsidiary Experion Biotechnologies Inc. (“Experion or “the Company’’), a Health Canada licensed cultivator and processor of Cannabis has signed a Letter of Intent (“LOI”) with the Société québécoise du cannabis (“SQDC”) Québec’s sole legal retailer of recreational cannabis, to supply Adult-Use cannabis products to the SQDC for distribution and sale in the Province of Québec.

 

Mr. Jay Garnett, Chief Executive Officer, commented “We are pleased to work with the SQDC and deliver products that will meet the demand of its customers. This agreement further solidifies Experion’s position in Canada’s legal adult use cannabis marketplace expanding our distribution beyond British Columbia and Saskatchewan”

 

Under the terms of the LOI, Experion through its wholly owned Kanabé Goods Co. (‘’ Kanabé”), an adult-use health & wellness brand, will supply products in the form of THC and CBD oil capsules. Shipments to Québec are scheduled to start in December and continue throughout 2020.

 

Ms. Krystal Laferriere, Experion’s Cannabis Wellness Expert and Co-Founder of Kanabé Goods Co. who had created the product line to soothe side-effects and other ailments suffered as a result of her Crohn’s Disease, commented, “Part of Experion’s growth strategy is focused on establishing a strong national footprint and building our brand presence. It is a great accomplishment to have Québec as Kanabé’s entry point into the domestic market. Our capsules will serve those looking for a micro-dose, option made from our full spectrum oil. Kanabé will also roll out more products such as oral sprays. We are proud to have this opportunity to partner with Québec and the SDQC to help ensure Canadians have access to a reliable supply of adult-use cannabis products”

 

About Kanabe Goods Co.

Kanabé Goods Co. www.kanabe.ca creates therapeutic health and wellness products containing cannabis and has over 50 formulations in its portfolio including topical salves, lotions, oils as well as edible oils and capsules. Kanabé products were developed to target and soothe various aliments by combining cannabinoids, terpenes and aromatherapy with a focus on discretion and ease of use by developing products that are already found in consumers everyday life. Kanabé is an adult-use, over-the-counter health & wellness brand ingraining into daily actions and rituals for comfort and solutions to acute problems ranging from sore muscles, to sleep and skin issues.

 

About Experion Holdings Ltd.

Experion Holdings Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC; and EFX Laboratories Inc., a medical products production and clinical research company based in Calgary, AB.

Experion Holdings Ltd. is invested in a portfolio of products to address a wide spectrum of consumer needs’ including Medical, Adult-use, and Wellness and Therapeutic products.

Experion trades on the TSX Venture Exchange as a Tier 1 issuer under the symbol “EXP” on the OTCQB Venture under the symbol “EXPFF” and on the Frankfurt Stock Exchange under the symbol “MB31” For further information, please visit the Company’s website www.experionwellness.com or join our Global Investor Forum on 8020 http://connects.company/ExperionEXP where you can read all press releases or contact Investor Relations, Judy-Ann Pottinger, Phone: 604- 617-5290 Email: judy-ann@experionwellness.com

 

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct. Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

 

__________________

 

Experion Holdings Ltd. Signature d’une lettre d’intention avec la Société québécoise du Cannabis (SQDC) pour la distribution et la vente de produits de cannabis dans la province

 

VANCOUVER, BC et MONTRÉAL, QC, 10 septembre, 2019 (FSCwire) Experion Holdings Ltd. (TSXV: EXP) (OTCQB:EXPFF) (FRANKFURT:MB31), anciennement Viridium Pacific Group Ltd a annoncé aujourd’hui que sa filiale en propriété exclusive Experion Biotechnologies Inc. (« Experion » ou « la compagnie »), un cultivateur et transformateur de cannabis autorisé par Santé Canada, a signé une lettre d’intention(« LI ») avec la Société québécoise du cannabis (“SQDC”) le seul détaillant légal de cannabis récréatif au Québec, pour lui fournir des produits de cannabis pour les adultes pour une distribution et une vente dans la province de Québec.

 

M. Jay Garnett, chef de la direction, a déclaré: « Nous sommes heureux de travailler avec la SQDC et de livrer des produits qui répondront à la demande de nos clients. Cet accord renforce la position d’Experion sur le marché canadien de l’usage légal du cannabis pour les adultes et étend notre distribution au-delà de la Colombie-Britannique et de la Saskatchewan ».

 

Aux termes de la lettre d’intention, Experion, par l’entremise de Kanabé Goods Co. (« Kanabé »), une marque de produits de santé et de bien-être pour adultes, fournira des produits sous forme de capsules d’huile de THC et de CBD. Les expéditions vers le Québec devraient débuter en décembre et se poursuivre tout au long de l’année 2020.

 

Mme Krystal Laferrière, experte chez Experion Cannabis Wellness et co-fondatrice de Kanabé Goods Co, a commenté: “Une partie de la stratégie de croissance d’Experion est axée sur l’établissement d’une forte empreinte nationale et le renforcement de notre présence de marque. C’est une grande réalisation que d’avoir le Québec comme point d’entrée de Kanabé sur le marché intérieur. Nos capsules serviront à ceux qui recherchent une microdose, option faite à partir de notre huile à spectre complet. Kanabé lancera également d’autres produits comme les vaporisateurs oraux. Nous sommes fiers d’avoir l’occasion de travailler en partenariat avec le Québec et la SQDC pour aider à assurer aux Canadiens un approvisionnement fiable en produits de cannabis destinés aux adultes”.

 

À propos de Kanabé Goods Co.

Kanabé Goods Co. www.kanabe.ca crée des produits thérapeutiques de santé et de bien-être contenant du cannabis et compte plus de 50 formulations dans son inventaire, y compris des pommades topiques, des lotions, des huiles ainsi que des huiles et capsules comestibles. Les produits Kanabé ont été développés pour cibler et apaiser différents aliments en combinant les cannabinoïdes, les terpènes et l’aromathérapie avec un souci de discrétion et de facilité d’utilisation en développant des produits déjà présents dans la vie quotidienne des consommateurs. Kanabé est une marque de santé et de bien-être en vente libre pour les adultes et qui s’insère dans les actions et les rituels quotidiens pour le confort et les solutions aux problèmes aigus allant des douleurs musculaires aux problèmes de sommeil et de la peau.

 

À propos de Experion Holdings Ltd.

Experion Holdings Ltd est la société mère d’Experion Biotechnologies Inc, un cultivateur et transformateur de cannabis autorisé par Santé Canada, dont le siège social est situé à Mission, en Colombie-Britannique, et de EFX Laboratories Inc, une société de production de produits médicaux et de recherche clinique située à Calgary, en Alberta.

Experion Holdings Ltd investit dans une gamme de produits destinés à répondre à un large éventail de besoins des consommateurs, notamment des produits médicaux, des produits pour adultes et des produits de bien-être et thérapeutiques.

 

Experion se transige à la Bourse de croissance TSX à titre d’émetteur de niveau 1 sous le symbole « EXP » sur la Bourse de croissance OTCQB sous le symbole « EXPFF » et à la Bourse de Francfort sous le symbole « MB31 ». Pour plus d’informations, veuillez visiter le site Web de la Société www.experionwellness.com ou rejoindre notre forum d’investisseur global au 8020 http://connects.company/ExperionEXP où vous pouvez lire tous les communiqués de presse ou contacter les relationnistes pour les investisseurs, Judy-Ann Pottinger, tél.: 604 617-5290 courriel judy-ann@experionwellness.com

 

Divulgation
Le présent communiqué de presse contient de l’information prospective au sens des lois canadiennes sur les valeurs mobilières. Bien que la Société estime que cette information est raisonnable, elle ne peut donner aucune assurance que ces attentes se révéleront exactes. L’information prospective se reconnaît habituellement à l’emploi de mots tels que: croire, s’attendre à, prévoir, avoir l’intention de, estimer, prévoir, postuler et d’autres expressions semblables, ou sont ceux qui, par leur nature même, renvoient à des événements futurs. La Société met en garde les investisseurs contre le fait que toute information prospective fournie par la Société ne garantit pas les résultats ou le rendement futur et que les résultats réels peuvent différer sensiblement de ceux qui figurent dans l’information prospective en raison de divers facteurs, notamment la situation des marchés financiers des titres de participation de la Société, la volatilité récente des marchés, la capacité de la Société à mobiliser les capitaux nécessaires ou à être pleinement en mesure de réaliser ses stratégies commerciales, les risques identifiés dans l’énoncé déposé et les autres risques et facteurs dont la Société ignore pour le moment, mais non exclusivement: la conjoncture actuelle sur les marchés des actions de la Société, la récente instabilité des marchés, l’incapacité de la Société d’obtenir les capitaux dont elle a besoin et d’être en mesure d’adopter sa stratégie d’affaires, et les risques identifiés dans la Déclaration de changement de l’information financière. Le lecteur est prié de se reporter à la déclaration de changement à l’inscription datée du 25 septembre 2017 ou au rapport de gestion annuel et intermédiaire le plus récent pour une analyse plus complète de ces facteurs de risque et de leurs effets potentiels, dont des exemplaires sont disponibles sur la page de la Société sur SEDAR www.sedar.com.

, , , , , , , , , , , , , , , , , , , , , , , , ,

Experion Holdings Ltd. Trading on Frankfurt Stock Exchange Under New Company Name

VANCOUVER, British Columbia, July 3, 2019 (FSCwire) Experion Holdings Ltd. (“Experion” or the “Company”) (TSXV: EXP) (OTCQB:EXPFF) (FRANKFURT:MB31), formerly Viridium Pacific Group Ltd., announced today that its shares are now trading on the Frankfurt Stock Exchange under the Company’s new name Experion Holdings Ltd.  The symbol and WKN have not changed and remains ‘’MB31” and ‘’WKN:A2PLZG”. 

The Company’s shares continue to be listed on the TSXV under the ticker ‘’EXP” and on the OTCQB market in the US under the ticker “EXPFF”

Mr. Jay Garnett, Chief Executive Officer commented, “Experion is pursuing international growth strategies, such as the vast export market in countries with early opportunities.  Having our new name reflected on the Frankfurt Stock Exchange will allow us to grow our shareholder base throughout Europe and attract global recognition as we work diligently to unlock value for our current shareholders and new shareholders to come”

The Frankfurt Stock Exchange is one of the world’s largest trading centres for securities. With a share in turnover of around 90 per cent, it is the largest of Germany’s seven stock exchanges and it is an international trading centre, which is reflected in the structure of its participants. Of the approximately 200 market participants, roughly 50% are from countries other than Germany.

On June 25th Experion announced an LOI with a Polish Import and Distribution Company.  The LOI will see Experion exporting medical flower products to Poland for scientific purposes enabling the Polish Company to test and develop Experion’s flower products.  Ultimately Experion’s goal is to export increased quantities of its flower products into Poland for medical use.

Mr. Jay Garnett further commented “As investor interest and momentum in the cannabis industry continues to accelerate, Experion will be well-positioned to participate in the European and global cannabis markets as they continue to expand, and we receive our EU GMP certification that will allow Experion products to be exported across Europe.”

 

About Experion Holdings Ltd.

Experion Holdings Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC; and EFX Laboratories Inc., a medical products production and clinical research company based in Calgary, AB.

Experion Holdings Ltd. is invested in a portfolio of products to address a wide spectrum of consumer needs’ including Medical, Adult-use, and Wellness and Therapeutic products.

 

For further information, please visit the Company’s website www.experionwellness.com or contact:

 

Judy-Ann Pottinger, Investor Relations

Tel: (604) 617-5290

judy-ann@experionwellness.com

 

We invite all investors and other interested parties to join the Experion Holdings portal on 8020 Connect. Join here:  http://connects.company/Experion

 

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

, , , , , , , , , , ,

Experion Selling Starter Materials

March 7, 2019: Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: VIRFF) is pleased to announce its wholly owned subsidiary, Experion Biotechnologies Inc. (“Experion”), a licensed cultivation and processor under the Cannabis Act, has commenced clone sales as starting materials.  Its first sale of clones to another licensed Standard Cultivator headquartered British Columbia happened in January of this year, with several more sales including a 1,200-clone shipment to Alberta recently.

The buyers of Experion’s clones are newly licensed Standard Cultivators looking for quality genetics to launch their cultivation process. The sales expand Experion’s product line with clones exhibiting the desired specifications and attributes for both the medical and adult-use market.  Under the Cannabis Act, a cultivation license can sell product to other licensed facilities fostering new business to business relationships and the ability to create quick strategic partnerships as the market becomes established. All starting materials sold as clones to other cultivators have a flower buy back program with Experion. As well, Experion can also sell clones for medical purposes to qualified individuals as a licensed medical supplier.

Mr. Jarrett Malnarich, Viridium COO, commented, “We are very excited launching our clone business and looking forward to future sales with new and established cultivators across Canada. By supplying genetics, further conversations leading to partnerships and buy back programs often evolve and we look forward to developing more of these relationships through our starter materials sales program.”

About Viridium

 Viridium Pacific Group Ltd. is the parent company of operating subsidiaries involved in horticultural production (Experion Biotechologies Inc.), medical products production (EFX Labs), property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.). Experion Biotechnologies Inc. is a Health Canada licensed producer of cannabis, which operates outside of Mission, BC.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.

For further information:

Viridium Pacific Group Ltd.

Jarrett Malnarich
Tel: (604) 837-8688
info@viridiumpacific.com
www.viridiumpacific.com

Disclosure      

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

 

, , , , , , , , , , , ,

Viridium Announces Graduation from Tier 2 to Tier 1 of the TSX Venture Exchange

February 25, 2019 Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: VIRFF) is pleased to announce it has met the requirements of Tier 1 on the TSX Venture Exchange effective February 25, 2019. Tier 1 is reserved for the most advanced issuers with the most significant financial resources on the TSX Venture Exchange.

Jay Garnett, Viridium’s President and Chief Executive Officer commented: “Viridium’s graduation to Tier 1 of the TSX Venture Exchange is a further demonstration of the quality of our company’s strength with the recent merging with EFX and of our management team. Graduating to Tier 1 status will provide the Company with a more favorable regulatory environment, decreased filing requirements and increased opportunity for participation by institutional investors. We would like to thank the TSX Venture Exchange for recognizing Viridium’s rapid growth over the past couple of years, which was demonstrated by Viridium’s license with Health Canada to grow and sell its medical cannabis.”


About Viridium

 Viridium Pacific Group Ltd. is a consumer wellness and biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production, (Experion Biotechologies Inc.), medical product production (EFX Labs), property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.). Experion Biotechnologies Inc., is a Health Canada licensed cultivator and processor of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.


For further information:
www.viridiumpacific.com
Jarrett Malnarick,
Info@viridiumpacific.com
604 837 8688

Disclosure      

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

 

, , , , , , , , , , , , ,

Viridium Completes Acquisition of EFX Laboratories

February 11, 2019: Viridium Pacific Group Ltd. (“Viridium”) (TSXV: VIR) (OTCPink: VIRFF) is pleased to announce it has completed the acquisition of EFX Laboratories Inc. (“EFX”) it previously announced on January 7, 2019, by way of an amalgamation of EFX and 2163903 Alberta Ltd., a wholly-owned subsidiary of Viridium, in accordance with the Business Corporations Act (Alberta) (the “Amalgamation”).

Under the terms of the amalgamation agreement among Viridium, EFX and 2163903 Alberta Ltd., Viridium acquired all of the issued and outstanding class A voting shares of EFX (“EFX Shares”) on the basis of 1 common share of Viridium (a “Viridium Share”) for every 2.57 EFX Shares, resulting in the issuance of 49,412,781 Viridium Shares (including all EFX Shares issued in connection with the exercise of in-the-money EFX options). In addition, all out-of-the-money EFX stock options have been exchanged for an aggregate of 1,089,491 Viridium stock options.

EFX is a Canadian biotech company located in Calgary focused on medical cannabis applications and treatments and has developed several proprietary formulations for pain control, as well as a suite of value-added wellness products. Key products of EFX include a proprietary two piece pill for postoperative pain control actively being prepared for a phase III clinical trial and over 50 market tested wellness formulas and products ranging from creams, tinctures, sprays and oils.

“The acquisition of EFX deepens our focus in the medical cannabis industry,” states Viridium CEO Jay Garnett, “with the addition of EFX assets and its key people, we further our vision of supplying industry leading value added products formulated from our own cultivated cannabis”.

Animus Capital Partners Inc. (“Animus“) acted as exclusive financial advisor to Viridium in respect of the Amalgamation. Animus is a global financial advisory and merchant banking firm based in Calgary, Alberta. Animus is focused on investing, advising and partnering with leading companies in select industries.

Mathew August, Executive Managing Director of Animus Capital Partners, commented “this creates a preeminent leading biotech focused company with tier one management, board governance and a business strategy that attracts institutional capital and market interest going forward”.

Management and Board of Directors

Viridium’s board of directors is now comprised of five existing Viridium directors (Jay Garnett, Harry McWatters, Sean MacNeil, Benjamin Eastwood and Dan Echino) and two former EFX directors (Michael Kohut and Michael Black). In order to accommodate the new board members, Viridium wishes to thank Jarrett Malnarick and Gary Purewal, who have stepped down and resigned as directors, for their valuable contributions to Viridium’s board. Viridium’s management team is unchanged, being comprised of Jay Garnett (President and Chief Executive Officer) and Jarrett Malnarick (Senior Vice President and Chief Operating Officer).

Strategic Rationale

Viridium believes that the Amalgamation is consistent with Viridium’s stated goal of producing a strong portfolio of cannabis brands and products for the Canadian medical, wellness, and export markets and that the financial and strategic benefits of the Amalgamation are uniquely compelling to its shareholders. Viridium anticipates that the Amalgamation will position it for a strong go-forward strategy to create a long term sustainable growth company focused on the “3rd wave” of cannabis investment which will include biotech applications in the medical, retail consumer wellness product market.

The Amalgamation is expected to accelerate the completion of Viridium’s business initiatives in the next 24 to 36 months. The combined company is fully-funded to execute its business initiatives with a strong balance sheet with more than $10 million cash on hand. Viridium, as combined with EFX, is now vertically integrated from seed to value added product, with all of the Health Canada licences required to execute its business strategy.

Trading Halt

Viridium expects that the halt on Viridium Shares will be lifted by the TSX Venture Exchange (the “Exchange”) today, February 11, 2019.

About Viridium

Viridium is a consumer wellness and biotech innovation company based in British Columbia, and the parent company of Experion Biotechnologies Inc. (“Experion”), a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, British Columbia. Experion currently a cultivation and processing license issued under the Cannabis Act.

Reader Advisory

Investors are cautioned that any information released or received with respect to the Amalgamation may not be accurate or complete and should not be relied upon.

The Exchange has in no way passed upon the merits of the Amalgamation and has neither approved nor disapproved of the contents of this news release.

Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Further Information

www.viridiumpacific.com

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”). The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking statements. More particularly and without limitation, this news release contains forward-looking statements concerning Viridium’s goals, strategy, business plan and capitalization; the  benefits of the Amalgamation; the cannabis industry and investment therein, Health Canada licenses; and the Exchange’s halt on Viridium Shares. The forward-looking statements are based on certain key expectations and assumptions made by Viridium, including, among other things the success of Viridium’s and EFX’s operations as a combined entity, expected growth, results of operations, performance, industry trends and growth opportunities, and synergies expected to result from the Amalgamation Although Viridium believes that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Viridium can give no assurance that they will prove to be correct. By their nature, forward-looking statements are subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. These risks and uncertainties, include, but are not limited to unforeseen difficulties or delays in integrating the assets of EFX into Viridium’s operations, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability of Viridium to implement its goals, strategies and business plans; competition; currency and interest rate fluctuations and other risks.  Readers are cautioned not to place undue reliance on the forward-looking statements, which are given as of the date hereof, and to not use such forward-looking statements for anything other than their intended purpose. Viridium undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

, , , , , , , , , , , , , , , ,

Stand for Something

Subscribe to our newsletter for updates
and curated content delivered to: